Compare RDNT & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDNT | SRRK |
|---|---|---|
| Founded | 1985 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.2B |
| IPO Year | 1996 | 2018 |
| Metric | RDNT | SRRK |
|---|---|---|
| Price | $69.96 | $48.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 18 |
| Target Price | ★ $97.00 | $70.06 |
| AVG Volume (30 Days) | 700.0K | ★ 1.5M |
| Earning Date | 11-08-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,616,630,000.00 | N/A |
| Revenue This Year | $23.26 | N/A |
| Revenue Next Year | $13.17 | $662.10 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 13.05 | N/A |
| 52 Week Low | $50.82 | $38.69 |
| 52 Week High | $85.84 | $61.76 |
| Indicator | RDNT | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 39.28 | 56.01 |
| Support Level | $67.52 | $44.88 |
| Resistance Level | $72.80 | $50.56 |
| Average True Range (ATR) | 3.60 | 2.95 |
| MACD | -0.92 | 0.48 |
| Stochastic Oscillator | 12.33 | 57.77 |
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostic.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.